TABLE 1.
Patient and donor characteristics
| Immunosuppression |
|||
|---|---|---|---|
| SRL based (n=88) | CNI based (n=53) | P | |
| Recipient age, years, mean (range) | 51.3 (42–74) | 50.8 (28–63) | 0.7 |
| Male sex, n (%) | 71 (80.6) | 40 (75.4) | 0.52 |
| Diabetes mellitus, n | 22 | 12 | 0.8 |
| Non-Caucasian, n (%) | 4 (4.5) | 10 (18.8) | 0.008 |
| Pretransplant dialysis, n | 10 | 0 | 0.01 |
| Hepatocellular carcinoma, n | 39 | 1 | <0.001 |
| MELD score at LT, mean ± SD | 17.8±9.5 | 13.8±7.5 | 0.02 |
| Body mass index, kg/m2 (mean ± SD) | 26.6±5.2 | 24.0±4.4 | 0.01 |
| Donor age, years, mean (range) | 42.5 (14–74) | 42 (16–69) | 0.6 |
| Cold ischemia time, min (mean ± SD) | 385±209 | 404±170 | 0.3 |
| Transplant era, n | |||
| 1998 to 2002 | 40 | 28 | 0.48 |
| 2003 to 2006 | 48 | 25 | 0.48 |
| Cumulative 12-month tacrolimus exposure, ng/mL (mean ± SD) | 4.9±2.9 | 7.5±3.9 | <0.001 |
| Cumulative 12-month cyclosporine exposure, ng/mL (mean ± SD) | 92±102 | 221±181.5 | 0.01 |
CNI Calcineurin inhibitor; LT Liver transplantation; MELD Model for End-stage Liver Disease; SRL Sirolimus